Emily C L Wong
Overview
Explore the profile of Emily C L Wong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wong E, Dulai P, Marshall J, Jairath V, Reinisch W, Narula N
Inflamm Bowel Dis
. 2023 May;
30(2):311-313.
PMID: 37186256
No abstract available.
12.
Wong E, Merat S, Monaco C, Dulai P, Jairath V, Marshall J, et al.
Dig Dis Sci
. 2023 Apr;
68(6):2635-2646.
PMID: 37119375
Objective: In the absence of head-to-head clinical trials, indirect comparative studies are needed to help position therapies in ulcerative colitis (UC). We aimed to compare the efficacy of infliximab vs....
13.
Wong E, Dulai P, Marshall J, Jairath V, Reinisch W, Narula N
Inflamm Bowel Dis
. 2023 Apr;
30(3):370-381.
PMID: 37116893
Introduction: We developed and internally validated a prognostic scoring index for ulcerative colitis (UC) patients that includes baseline patient-reported outcomes (PROs), biomarkers, endoscopy, and histology for achieving 1-year endoscopic improvement...
14.
Wong E, Dulai P, Hasan B, Marshall J, Reinisch W, Narula N
J Crohns Colitis
. 2023 Feb;
17(7):1114-1121.
PMID: 36821429
Background And Aims: Evaluating histological outcomes in ulcerative colitis [UC] has become common in recent clinical trials. In this study, we explored the additional value of the combined endpoint of...
15.
Narula N, Chang N, Mohammad D, Wong E, Ananthakrishnan A, Chan S, et al.
Clin Gastroenterol Hepatol
. 2023 Feb;
21(10):2483-2495.e1.
PMID: 36731590
Background & Aims: Several studies have been published on the association between food processing and risks of Crohn's disease (CD) and ulcerative colitis (UC), with some variability in results. We...
16.
Narula N, Wong E, Dulai P, Marshall J, Jairath V, Reinisch W
Dig Dis Sci
. 2023 Jan;
68(6):2658-2666.
PMID: 36645636
Background: Indirect treatment comparisons using patient-level data are increasing in popularity within inflammatory bowel disease research. We compared the efficacy of adalimumab and vedolizumab for biologic-naïve moderate-severe ulcerative colitis (UC)...
17.
Ma C, Panaccione R, Xiao Y, Khandelwal Y, Murthy S, Wong E, et al.
Am J Gastroenterol
. 2022 Dec;
118(5):861-871.
PMID: 36580497
Introduction: We aimed to evaluate the real-world effectiveness and safety of tofacitinib for the treatment of ulcerative colitis (UC). Methods: REMIT-UC is a Canadian multicenter cohort study. Standardized data collection...
18.
Narula N, Wong E, Pray C, Marshall J, Rangarajan S, Islam S, et al.
Clin Gastroenterol Hepatol
. 2022 Dec;
21(10):2649-2659.e16.
PMID: 36528284
Background & Aims: Several medications have been suspected to contribute to the etiology of inflammatory bowel disease (IBD). This study assessed the association between medication use and the risk of...
19.
Wong E, Dulai P, Marshall J, Jairath V, Reinisch W, Narula N
Inflamm Bowel Dis
. 2022 Nov;
29(9):1390-1398.
PMID: 36426810
Background: In placebo-controlled clinical trials for Crohn's disease (CD), some placebo-treated patients demonstrate improvement. However, it is unclear what factors contribute to placebo response and remission. Methods: This was a...
20.
Narula N, Wong E, Aruljothy A, Dulai P, Colombel J, Marshall J, et al.
J Clin Gastroenterol
. 2022 Oct;
57(9):913-919.
PMID: 36227009
Background: This analysis evaluates the association between baseline patient-reported symptom (PRS) severity in Crohn's disease (CD), including abdominal pain, stool frequency, general well-being, and achievement of clinical and endoscopic outcomes....